Market Overview

UPDATE: JP Morgan Initiates Infinity Pharmaceuticals at Overweight on Positive Data

Share:
Related INFI
Mid-Afternoon Market Update: GNC Gains On Upbeat Earnings; Barracuda Shares Drop
Mid-Morning Market Update: Markets Open Lower; Goldman Sachs Earnings Miss Estimates

JP Morgan initiated coverage on Infinity Pharmaceuticals (NASDAQ: INFI) with an Overweight rating and a $42.00 price target.

JP Morgan commented, "We are initiating coverage of Infinity Pharmaceuticals with an Overweight rating based on the potential of IPI-145, the company's wholly owned, possibly best-in-class oral drug candidate for the treatment of hematologic (blood) cancers, which we believe is a billion-dollar-plus opportunity. In our view, 2013 is shaping up as another event-driven year for INFI. The stock has had an impressive run, we believe based on promising early data and recent market precedent (set by PCYC in particular)."

Infinity Pharmaceuticals closed at $33.37 on Wednesday.

Latest Ratings for INFI

DateFirmActionFromTo
Jun 2016William BlairDowngradesOutperformMarket Perform
Jun 2016JefferiesDowngradesBuyHold
Jun 2016Morgan StanleyDowngradesOverweightEqual-Weight

View More Analyst Ratings for INFI
View the Latest Analyst Ratings

Posted-In: JP MorganAnalyst Color Initiation Analyst Ratings

 

Related Articles (INFI)

View Comments and Join the Discussion!